

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-26 (canceled).

27 (currently amended). A compound of ~~Formula I~~ selected from ~~3-Ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide~~; 3-ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide and pharmacologically acceptable salts thereof.

28 (currently amended). A method of treating ~~cancer~~ a cancer selected from cervical carcinoma, colon carcinoma and non-small cell lung cancer, comprising the ~~step~~ steps of (1) administering a compound as claimed in claim 27 in a therapeutically effective amount to tumour cells in a subject, wherein the tumour cells are in a hypoxic environment, and (2) administering radiotherapy to the tumour cells before, during or after the administration of the compound as defined in claim 27 to the tumour cells.

29-30 (canceled).

31 (currently amended). The method as claimed in claim ~~30~~ 28 further including the step of administering one or more chemotherapeutic agents to the tumour

cells before, during or after the administration of the compound as defined in claim 27 to the tumour cells.

32 (previously presented). The method as claimed in claim 31 wherein the one or more chemotherapeutic agents is selected from Cisplatin or other platinum-based derivatives, Temozolomide or other DNA methylating agents, cyclophosphamide or other DNA alkylating agents, Doxorubicin, mitoxantrone, camptothecin or other topoisomerase inhibitors, Methotrexate, gemcitabine and/or Docetaxel or other taxanes.

33 (currently amended). A method of radiosensitising in a subject tumour cells of solid tumours selected from the group consisting of cervical carcinoma, colon carcinoma and non-small cell lung cancer in hypoxic conditions *in vivo*, comprising the steps of:

(a) administering to the subject a pharmaceutical composition in an amount sufficient to produce radiosensitivity in the tumour cells, the composition comprising a compound as claimed in claim 27; and

(b) subjecting the tumour cells to radiation.

34-35 (canceled).

36 (previously presented). A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 27 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.